Table 1 Baseline data for patients with polymyositis and dermatomyositis and healthy controls.
Patients* n= 23 Median (range) | Healthy controls* n= 12 Median (range) | Exercise group*¤ n= 9 Median (range) | Control group*¤ n= 7 Median (range) | |
|---|---|---|---|---|
Sex (female/male), n | 17/6 | 9/3 | 8/1 | 6/1 |
Diagnosis (PM/DM), n | 11/12 | NA | 4/5 | 3/4 |
Age, years | 58 (37 to 77) | 51 (31 to 71) | 60 (48 to 72) | 58 (42 to 77) |
Duration since diagnosis, years | 7 (1 to 33) | NA | 8 (1 to 13) | 7 (2 to 33) |
DMARD treatment (GC/MTX/AZA/RITUX/MMF/CsA), n | 13/9/5/2/1/1 | NA | 5/3/3/0/1/0 | 5/2/2/1/0/1 |
Daily GC dose, mg | 5 (1 to 10) | NA | 5 (1 to 8) | 2 (2 to 5) |
MMT-8, 0 to 80 | 75 (42 to 80) | NA | 76 (42 to 79) | 73 (57 to 77) |
HAQ, 0.0 to 3.0 | 0.5 (0.0 to 1.8)1 | NA | 0.5 (0.0 to 1.4)1 | 0.5 (0.4 to 1.8) |
CPK, μcat/l | 2 (1 to 62)3 | NA | 2 (1 to 62)1 | 2 (1 to 4)1 |
Physician global disease activity VAS, 0 to 100 | 4 (8 to 16)2 | NA | 4 (0 to 14)1 | 2 (0 to 10)1 |
Patient global disease activity VAS, 0 to 100 | 39 (0 to 88)1 | NA | 24 (0 to 72)1 | 42 (3 to 77) |
MITAX, 0 to 1.0 | 0.1 (0.0 to 0.2)2 | NA | 0.1 (0.0 to 0.2) | 0.1 (0.1 to 0.2)1 |
Muscle disease activity, VAS, 0 to 100 | 2 (0 to 8)2 | NA | 2 (0 to 8)1 | 2 (0 to 7)1 |
Physician global damage VAS, 0 to 100 | 18 (0 to 62)2 | NA | 22 (7 to 62)1 | 22 (10 to 49)1 |
Muscle damage VAS, 0 to 100 | 11 (0 to 39)2 | NA | 10 (0 to 39)1 | 14 (9 to 31)1 |